✅ The facility now has two 4,000L fermenters and a new GMP license.
📈 Michael De Marco highlighted the growing demand for microbial manufacturing due to the complexity of biotech projects.
🔧 This upgrade enhances Lonza’s ability to adapt to various customer needs in biologics production.
Introduction:
The article reports on Lonza’s completion of an expansion at its microbial manufacturing facility located in Visp, Switzerland. This facility has recently obtained a Good Manufacturing Practice (GMP) license, enhancing Lonza’s capabilities in biologics production through microbial fermentation.
- Lonza’s Visp facility has been expanded to include additional capacity for mid-scale microbial manufacturing, featuring two 4,000L fermenters.
- The facility received a GMP license after an audit by Swissmedic, which allows for the compliant manufacturing and release of biologics.
- Incorporation of automation technologies, such as an electronic manufacturing execution system and sensor integration, is central to the facility’s operations.
- The demand for microbial manufacturing is increasing due to the growing complexity and diversity of the biotech pipeline, including next-generation molecules.
- This expansion enables Lonza to offer increased flexibility to adapt to varying production demands throughout the lifecycle of their clients’ products.
Conclusion:
Lonza’s expansion of its microbial manufacturing facility is a strategic response to the rising demand for complex biologics in the biotech industry. By enhancing operational capacity and incorporating advanced automation, Lonza positions itself as a robust partner in the biopharmaceutical supply chain, capable of meeting evolving market demands.
